


## Management of muscle-invasive bladder cancer



<sup>1</sup> At the time of publication (February 2015) neither mitomycin or [5-FU] had a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

<sup>2</sup> Although this use is common in UK clinical practice, at the time of publication (February 2015), carbogen and nicotinamide did not have UK marketing authorisation for this indication. . The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.